Oncology

Review top news and interview highlights from the week ending September 29, 2023.

Around half of patients with R/R large B-cell lymphoma are considered ineligible for autologous stem cell transplant and are thus ineligible for the approved indication of Yescarta.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The associate professor at MD Anderson Cancer Center discussed the upcoming trial of NY-ESO-1 TCR/IL-15 NK cell therapy for SS and MRCLS.

Notably, the trial is assessing intravenous administration of PRGN-3005 against intraperitoneal administration in 2 separate cohorts.

Review top news and interview highlights from the week ending September 22, 2023.

The FDA issued a CRL for the therapy, to be marketed as Ryoncil, in August 2023.

J. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.

Cells from patients with ALL treated in the CARPALL study were analyzed and sequenced.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The trial has dosed its third patient, and, safety validation pending, plans to dose a second cohort beginning at the end of 2023.

The companies plan to evaluate the combination therapy in patients with HL in the phase 2 LuminICE-203 clinical trial.

The FDA has accepted the company’s plan to address its current IND clinical hold on HEMO-CAR-T.

Review top news and interview highlights from the week ending September 15, 2023.

The chief scientific officer at Omega Therapeutics discussed the issues with other modes of therapies that OEC therapy may address.

Patients were newly diagnosed and had acute myeloid leukemia positive for FLT3-iTD mutations.

A final analysis of data from CARTITUDE-1 was also presented at SOHO 2023, which revealed a PFS of 24.9 months in treated patients.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Adstiladrin was approved in December 2022 and is now available for select patients under an Early Experience Program.

SynKIR-110 is based off of the KIR-CAR platform developed at the University of Pennsylvania.

Beam Therapeutics also expects to announce initial data from its BEACON trial in sickle cell in 2024.

Review top news and interview highlights from the week ending September 8, 2023.

The chief development officer of Anixa Biosciences discussed the company’s trial of a CAR-T in ovarian cancer that is looking at the effect of regional administration and lymphodepletion on efficacy.

The CAR T-cell therapy, marketed as Yikaida in China, has been approved for second-line treatment for patients with refractory/relapsed large B-cell lymphoma.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The assistant professor at University College Dublin discussed challenges and different approaches to using microRNA in preclinical models of osteosarcoma.

The chief development officer of Anixa Biosciences discussed how the company is tackling 2 major challenges presented by solid tumors in its ovarian cancer clinical trial.

Stephen Gottschalk, MD, is using grant funding from ACGT to develop CAR T-cell therapy to treat children with sarcomas. He spoke about the challenges of treating sarcomas, the need for new therapies, and the importance of ACGT.

ACGT recently awarded a half-million dollar grant to brain cancer researcher Juan Fueyo, MD, who is developing an oncolytic virus therapy to treat the brain cancer glioblastoma.

September is Childhood Cancer Awareness Month, serving as a chance to assess what progress has been made in advancing cell and gene therapy research for children with cancer.